We are live on ! Find out more
BB

BB Biotech Portfolio holdings

AUM $3.98B
1-Year Est. Return 15.47%
This Fund
S&P 500
This Quarter Est. Return
-16.52%
1 Year Est. Return
+15.47%
3 Year Est. Return
+121.5%
5 Year Est. Return
+265.65%
10 Year Est. Return
–
AUM
$3.12B
AUM Growth
-$658M
Cap. Flow
+$105M
Cap. Flow %
3.38%
Top 10 Hldgs %
64.02%
Holding
36
New
4
Increased
20
Reduced
3
Closed
2

Top Buys

Rank Stock Value
1
MRNA icon
Moderna
MRNA
+$78.6M
2
AGIO icon
Agios Pharmaceuticals
AGIO
+$42M
3
SAGE
Sage Therapeutics
SAGE
+$34.8M
4
SRRK icon
Scholar Rock
SRRK
+$24.7M
5
NKTR icon
Nektar Therapeutics
NKTR
+$21.6M

Top Sells

Rank Stock Value
1
TSRO
TESARO, Inc.
TSRO
+$114M
2
CELG
Celgene Corp
CELG
+$50.2M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$48.3M
4
GILD icon
Gilead Sciences
GILD
+$43.5M
5
ACHN
Achillion Pharmaceuticals
ACHN
+$4.71M

Sector Composition

Rank Sector Weight
1 Healthcare 96.46%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VYGR icon
26
Voyager Therapeutics
VYGR
$190M
$26.9M 0.86%
2,865,841
+43,200
+2% +$554K
REGN icon
27
Regeneron Pharmaceuticals
REGN
$72.9B
$25.5M 0.82%
68,156
-131,844
-66% -$48.3M
ITCI
28
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$25.1M 0.8%
2,200,000
– –
KZR
29
DELISTED
Kezar Life Sciences
KZR
$19.3M 0.62%
+81,843
New +$20M
BOLD
30
DELISTED
Audentes Therapeutics, Inc
BOLD
$16.4M 0.53%
+769,404
New +$19.9M
SGMO
31
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$15.5M 0.5%
+1,350,000
New +$16.8M
NVAX icon
32
Novavax
NVAX
$1.23B
$15.3M 0.49%
416,500
– –
GTHX
33
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$12.9M 0.41%
671,925
+246,607
+58% +$9.24M
CDTX
34
DELISTED
Cidara Therapeutics
CDTX
$5.39M 0.17%
114,764
– –
ACHN
35
DELISTED
Achillion Pharmaceuticals
ACHN
– –
-1,279,340
Closed -$4.71M
TSRO
36
DELISTED
TESARO, Inc.
TSRO
– –
-2,931,802
Closed -$114M
1
2

Similar funds

SBAM
Santa Barbara Asset Management Los Angeles, California $6.43B AUM 10.99% 1-Year Est. Return
HFS
HL Financial Services Louisville, Kentucky $6.5B AUM 9.56% 1-Year Est. Return
SA
SQ Advisors Naples, Florida $1.32B AUM 10.3% 1-Year Est. Return
WF
WealthTrust Fairport Cleveland, Ohio $1.06B AUM 3.47% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
AB
AT Bancorp Dubuque, Iowa $823M AUM 0.35% 1-Year Est. Return
MFBTD
MB Financial Bank - Trust Department Rosemont, Illinois $816M AUM 5.49% 1-Year Est. Return

BB Biotech's Q4 2018 Portfolio in Review

As of Q4 2018, BB Biotech held 36 positions worth $3.12B, down 17% from $3.78B the previous quarter. Its ten largest holdings account for 64% of the portfolio.

BB Biotech deployed $105M of net new capital in Q4 2018, opening 4 new positions and adding to 20 existing holdings. Its largest new stake was Moderna: 4,785,681 shares worth $73.1M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 97% a quarter earlier.

On the sell side, the largest reduction was Celgene Corp, an estimated $50.2M trimmed.

  • BB Biotech's largest Q4 2018 buy was Moderna: 4,785,681 shares worth $73.1M.
  • BB Biotech added most to Agios Pharmaceuticals in Q4 2018, an estimated $42M increase.
  • BB Biotech's biggest Q4 2018 reduction was Celgene Corp, cutting an estimated $50.2M.
  • BB Biotech fully exited TESARO, Inc. in Q4 2018, selling an estimated $114M.
  • BB Biotech's ten largest holdings make up 64% of its $3.12B portfolio in Q4 2018.
  • BB Biotech opened 4 new positions and closed 2 in Q4 2018.
  • BB Biotech's portfolio value fell 17% quarter-over-quarter to $3.12B.

Based on BB Biotech's 13F filing for Q4 2018, filed 12 Feb 2019.